IMMUNOCORE HOLDINGS PLC

IMMUNOCORE’s Q2 2026 results show KIMMTRAK’s 18% revenue jump, first‑half profit and strong cash reserve—signaling a shift from development to revenue‑generating success.

Immunocore’s R&D overhaul: new CSO, key exits and a faster path to T‑cell therapy milestones—boosting investor confidence and pipeline momentum.

Immunocore’s 2026 roadmap shows how a UK‑based biotech can shift from niche to industry‑leading, expanding KIMMTRAK, PRAME and HIV trials to unlock massive upside—UBS says it’s a “Buy” with 67% upside potential.

Immunocore Holdings PLC is navigating market volatility with a focus on innovation, developing transformative medicines for cancer, infection, and autoimmune diseases, while maintaining a commitment to patient care and improving outcomes.